Swedbank AB Sells 107,240 Shares of Gilead Sciences, Inc. $GILD

Swedbank AB reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,398,000 shares of the biopharmaceutical company’s stock after selling 107,240 shares during the quarter. Swedbank AB’s holdings in Gilead Sciences were worth $334,209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Kiley Juergens Wealth Management LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at $235,000. Canvas Wealth Advisors LLC purchased a new stake in Gilead Sciences in the 1st quarter worth about $215,000. O Domhnaill Enterprises Inc. purchased a new stake in Gilead Sciences in the 1st quarter worth about $2,118,000. Walser Wealth Management Company A Ltd Liability Co raised its stake in Gilead Sciences by 7.6% in the 1st quarter. Walser Wealth Management Company A Ltd Liability Co now owns 1,905 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 135 shares during the period. Finally, Hodges Capital Management Inc. raised its stake in Gilead Sciences by 1.7% in the 1st quarter. Hodges Capital Management Inc. now owns 8,718 shares of the biopharmaceutical company’s stock valued at $1,215,000 after acquiring an additional 146 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GILD. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target on the stock. Rothschild & Co Redburn dropped their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Truist Financial cut their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday. Finally, HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $133.00 to $155.00 in a research note on Monday. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $159.19.

Gilead Sciences Price Performance

Shares of GILD stock traded up $4.44 during trading hours on Tuesday, reaching $134.05. The stock had a trading volume of 2,526,462 shares, compared to its average volume of 7,199,889. The stock’s fifty day simple moving average is $129.44 and its 200 day simple moving average is $134.64. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The firm has a market capitalization of $166.43 billion, a PE ratio of 18.26 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,000 shares of company stock worth $10,824,500 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.